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NATRIURETIC PEPTIDES AS A HUMORAL LINK BETWEEN THE
HEART AND THE GASTROINTETSINAL SYSTEM
Anteneh Addisu
ABSTRACT
Natriuretic peptides are a family of hormones released by several
different tissues and exert various physiological functions by coupling
with cell surface receptors and increasing intracellular cyclic gyanylyl
monophosphate (cGMP). Atrial Natriuretic Peptide (ANP) and B-type
Natriuretic Peptide (BNP) are released in response to mechanical
stretch of the atrial or ventricular myocardium, respectively and their
plasma level is markedly elevated during myocardial infarction and
heart failure. Heart failure in turn is associated with symptoms
suggestive of perturbed gastrointestinal function such as nausea,
indigestion and malabsorption.
Intragastric pressure was monitored using a balloon catheter in
anesthetized mice. The pressure before and after treatment with a 10
ng/g intravenous dose of ANP, BNP, CNP or vehicle was compared and
analyzed.
intragastric

All

the

pressure

natriuretic
compared

peptides
to
viii

significantly

vehicle.

These

decreased

effects

were

attenuated or absent in natriuretic peptide receptor type-A (NPR-A)
knockout mice. Furthermore, the effect of BNP on gastric emptying
and intestinal absorption was examined using a meal consisting of
fluorescence

labeled

dextran

gavage

fed

to

awake

mice.

BNP

significantly decreased gastric emptying and absorption as compared
to vehicle control. Using a cryoinfarction acute myocardial injury
model, our investigation showed that mice with acute cryoinfarction
had a significantly lower gastric emptying and absorption of a gavage
fed meal compared to sham. Circulating BNP levels were significantly
higher in the infarcted mice compared to controls. Immunostaining
showed amplified distribution of the non-muscle myosin type-II (MCHII) in BNP treated mice. MCH-II is involved in movement of intestinal
villi.
In

summary,

natriuretic

peptides in general and BNP in

particular, have gastrointestinal effects including reduced gastric
contractility, emptying and absorption. In addition to their effect on
smooth muscle relaxation mediated by cGMP, natriuretic peptides
appear to have an effect on distribution of MHC-II in cells of the
intestinal villi.
We postulate that these effects are aimed at mediating a
‘communication’

between

the

cardiovascular

and

gastrointestinal

systems. Further characterization of such a link will not only add a
ix

dimension to the understanding of the pathophysiology of heart failure
but also enhances the search for further therapeutic targets.

x

CHAPTER ONE
INTRODUCTION AND BACKGROUND
Since maintaining body fluid volume is one of the most tightly
regulated

physiological

functions,

animals

have

evolved

with

increasingly sophisticated mechanisms for rapidly detecting and
responding to changes in fluid volume. In vertebrates, the vascular low
pressure volume sensors are embedded within the walls of the
myocardium and large pulmonary blood vessels. These volume sensors
detect changes in pressure (or volume) induced stretch of the vessel
and myocardial wall. Signals from these receptors travel via afferent
fibers of the vagus nerve to the solitary tract nucleus of the medulla
oblongata in the brain stem (Donald & Shepherd, 1979; Thorén et al.,
1976). Feedback activation or deactivation of neural signals back to
the target organs then modulate mechanisms that result in more or
less diuresis, natriuresis or vascular tone depending on the body’s
requirement. However even as early as the first half of the last century
there were studies that suggested there may be humoral (non
neuronal) system of receptors that responded to the change in

1

pressure or volume stretching the atrial myocardium. For instance,
expansion of plasma volume by blood transfusion to healthy dogs was
shown to increase urine flow (Metcalf, 1944). Similarly infusion of
isooncotic solution of albumin was shown to produce marked diuresis
in human volunteers (Welt & Orloff, 1951). Strauss et al reported that
infusion of isotonic (0.9%) saline to healthy volunteers increased
“water diuresis’’ during recumbency; and they noted that the body
position influenced how the infused volume is distributed and sensed
by the atrium (Strauss et al., 1951). The role of atrial stretch in such
volume induced diuresis was already experimentally established in the
mid 1950s (Henry & Pearce, 1956). Henry and colleagues used a
balloon to distend the atrium in dogs and showed that urine output
was increased corresponding to the degree of atrial distension. In their
paper entitled “The possible role of cardiac atrial stretch receptors in
the induction of changes in urine flow”, Henry and Pearce noted that
vagotomy did not abolish the diuretic response to isotonic infusions;
and this led to their conclusion in 1956 that “the body may be
provided with other receptors or pathways by which it receives
information which makes possible the regulation of blood volume by
the control of urine flow”.
Nevertheless, until only a little over two decades ago; the
outcome of the activation of atrial and venous stretch receptors was
2

believed to almost entirely depend on the modulation of autonomic
nerve activity or varying levels of secretion of antidiuretic hormone
(ADH) from the neurohypohysis.
In 1980 Adolfo de Bold reported his seminal discovery that
intravenous injection of extract from the rat atrium produced a marked
diuresis (de Bold et al., 1981).
Thus it became apparent that the atrium produced a diuretic and
natriuretic substance that was released into the circulation and worked
through a receptor system that is distinct from the neurally mediated
feedback inhibition. This natriuretic ‘substance’ was initially termed
atrial natriuretic factor (ANF). With this discovery, it also became
apparent that the heart has an endocrine function and directly
‘communicates’ with the kidney by virtue of its own cardiac hormone
systems.
The presence of granular structures in the atrial myocytes of
several different species was one of the earliest findings of the advent
of electron microscopy (Jamieson & Palade, 1964; Kisch, 1956; Palade,
1961). Moreover, the possible relationship between atrial granules and
the degree of sensitivity of the atrium to volume or salt loading was
suggested as early as 1976 (Marie et al., 1976). However it was with
de Bold’s seminal experiments that the content of these atrial granules
was clearly hinted to be a potent natriuretic substance that directly
3

influenced renal handling of salt and water (de Bold et al., 1981; de
Bold., 1985). The atrial natriuretic factor was later determined to be a
peptide produced by the atrial myocardium (Currie et al., 1984; Flynn
TG, 1983; Misono et al., 1984) and it is currently more commonly
referred to as Atrial Natriuretic Peptide (ANP). The ANP gene was
subsequently sequenced revealing the remarkable similarity and
genetic conservation of the natriuretic peptides across many species
(Seidman et al., 1984).

4

The Natriuretic Peptides
The identification of ANP in 1985 was soon followed by the
discovery of a similar peptide in porcine brain (Sudoh et al., 1988)
hence termed as brain natriuretic peptide (BNP). However it was later
discovered that BNP was another cardiac hormone and is actually
absent in brains of some species (Ogawa et al., 1991; Ogawa et al.,
1990). In 1990, C-type natriuretic peptide (CNP) was isolated from the
brain of pigs, bullfrogs and two species of teleost fishes (Sudoh et al.,
1990; Suzuki et al., 1991; Yoshihara et al., 1990). The three
natriuretic peptides share a common structural feature, a conserved
17 amino acid ring with variable N- and C-terminal sequences (figure
1). The number of amino acid residues extending from the C terminal
is usually 5 for ANP, 6 for BNP and 0 for CNP with few exceptions.
Thus the C-terminal sequence appears to be a major determinant of
biological activity of the natriuretic peptides. CNP is the most
conserved of the three peptides across species and it is believed to
have evolved earlier in the phylogenetic tree, ANP and BNP being
derived from it at a later point in evolution. In recent years a fourth
natriuretic peptide, a 38 amino acid peptide known as deandropsis
natriuretic peptide (DNP) has been isolated from the venom of the
green mamba snake (Munagala et al., 2004). Immunoreactivity to DNP
has been shown in human and rodent plasma (Johns et al., 2007;
5

Schirger et al., 1999). However, a gene coding for it has not yet been
isolated and the physiological significance of DNP in humans (if any)
remains poorly understood.

Figure 1. Linear peptide structure of the natriuretic peptides

Adapted from (Cea, 2005)
In humans, the ANP and BNP genes are localized in tandem on
chromosome 1. Transcription of the ANP gene yields an mRNA that
encodes a 151 amino acid metabolic precursor known as preproANP.
6

PreproANP is rapidly converted to a 126 amino acid peptide proANP.
ProANP is the predominant storage form of ANP and the major
constituent of atrial granules. Atrial distension is the major signal for
the release of ANP (Anderson et al., 1986; Dietz, 1984; Dietz et al.,
1991; Kinnunen et al., 1992; Sato et al., 1986). When such a signal is
sensed; proANP is cleaved by a cardiac serine protease (corin) into an
amino fragment pro-ANP (amino acids 1-98) and ANP, the biologically
active fragment (amino acids 99-126) (Bloch et al., 1986; Vuolteenaho
et al., 1985). Further cleavage of proANP (1-98) results in more
peptide fragments (1-30) and (31-67); these fragments also have
biological activity and neutralization of proANP 1-30 was shown to
exacerbate hypertension in spontaneously hypertensive rats (Dietz et
al., 2001; Dietz et al., 2003; Dietz et al., 1995; Dietz & Villarreal,
1995; Vesely et al., 1999). The amino acid sequences of the main
biologically active hormone ANP 99-126 are identical in all mammalian
species except at residue 110, which is methionine in humans
(Kangawa et al., 1984; Lewicki et al., 1986; Vlasuk et al., 1986) but
isoleucine in rats, mice and rabbits (Oikawa et al., 1985; Seidman et
al., 1984; Yamanaka et al., 1984). Alternate processing of the prepro
ANP in the kidney produces a 32 amino acid peptide known as
urodilatin. Urodilatin is secreted into the lumen of the distal nephron
(medullary collecting duct) where it is believed to be involved in
7

regulation of sodium and water absorption in the kidney (Forssmann et
al., 1998; Kuhn, 2005). Physiologically plasma ANP is markedly
increased

in

response

to

pressure

or

volume

overload

or

in

pathological states such as heart failure or ventricular hypertrophy.
However the plasma half life is rather short, averaging less than 3
minutes which indicates that the release of ANP serves to counteract
the effect of acute pressure or volume overload (Lang et al., 1985;
Ruskoaho, 1992).

Figure 2. Synthesis of natriuretic peptides and prohormones

Adapted from Koller and Goeddel 1992
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Human BNP is produced as a 132 amino acid residue preproBNP
that is subsequently cleaved to a 108 amino acid prohormone.
Additional cleavage yields the 32 amino acid active hormone and an
inactive 76 amino acid amino terminal (NT) fragment sometimes
known as NT-proBNP (Saito et al., 1989; Seilhamer et al., 1989;
Sudoh et al., 1988). Ventricular BNP is not stored in granules in the
myocytes, instead BNP production is regulated at the transcription
level by various stimuli, the main stimulus for BNP synthesis is stretch
of the ventricular wall by volume and/or pressure overload (Grépin et
al., 1994; Thuerauf et al., 1994). Even though the BNP gene is located
in tandem with the ANP gene; BNP expression doesn’t always parallel
ANP gene expression. The response of the BNP gene is quicker than
that of ANP suggesting a more acute and sustained role for BNP in
response to a volume overload. Increase in BNP mRNA is detected
within one hour of increased ventricular wall tension induced by
increased venous volume or acute myocardial infarction (Hama et al.,
1995; Nakagawa et al., 1995). BNP has a much longer half-life (than
ANP) of about 20 minutes (Espiner et al., 1995) and with sustained
cardiac stress; as in the case of heart failure, BNP mRNA levels have
been shown to remain increased (Tokola et al., 2001). BNP secretion
takes two forms, constitutive, where the BNP is secreted as fast as it is
being formed and a regulated pathway where the BNP is stored in
9

granules prior to being secreted (Kelly, 1985). Ventricular myocytes
shift between the two pathways depending on the stimulus, the
constitutive secretion being called upon when there is acute need for
BNP secretion and the regulated pathways operating when there is a
sustained myocardial stress such as chronic heart failure (Bloch et al.,
1986; Kelly, 1985).
CNP is mainly expressed in the brain, chondrocytes and
endothelial tissue. Myocardial tissue has a much smaller amount of
CNP than ANP or BNP and CNP is not stored in granules (Yandle,
1994). In humans, proCNP contains 103 amino acid residues and it is
cleaved to a 53 amino acid CNP in the brain, the heart and endothelial
tissue. Further cleavage yields a 22 amino acid peptide which is the
predominantly circulating form of CNP (Stingo et al., 1992; Totsune et
al., 1994; Wu et al., 2003). While CNP 53 is believed to be
predominantly a neurotransmitter, it is also involved in bone and
cartilage growth; CNP 22 is mainly involved in autocrine and paracrine
regulation of vascular tone (D'Souza et al., 2004). CNP has less effect
on diuresis and natriuresis than ANP or BNP and a more potent effect
on smooth muscle relaxation, it is thus believed to be mainly involved
in the regulation of coronary vascular tone in the heart (Clavell et al.,
1993; Komatsu et al., 1992; Sudoh et al., 1990).

10

Natriuretic Peptide Receptors
The

natriuretic

peptide

receptors

are

members

of

the

transmembrane guanylyl cyclase family of enzymes that are widely
distributed in human and animal tissues. There are at least seven
different guanylyl cyclase enzymes identified so far (Anand-Srivastava
& Trachte, 1993; Garbers et al., 2006). Natriuretic peptide receptor
(NPR) types A and B (NPR-A and NPR-B) are structurally similar and
exist as homodimers or homotetramers in intact mammalian cells
(Chinkers & Wilson, 1992; Iwata et al., 1991; Katafuchi et al., 1994).
The receptor consists of an extra cellular ligand-binding domain, a
membrane spanning domain and intracellular kinase-like and guanylyl
cyclase domains (Nagase et al., 1997; Potter, 2005). Both ANP and
BNP bind to NPR-A although ANP is known to bind with at least 10
times more affinity to NPR-A (Kambayashi et al., 1990; Nakao et al.,
1991). NPR-B has similar structure to NPR-A, but selectively binds to
CNP. Natriuretic peptide receptor type-C (NPR-C) has a short
intracellular sequence that doesn’t have a guanylyl cyclase domain.

11

Figure 3. Schematic representation of the natriuretic
peptide receptors

Adapted from Potter et al., 2006
Ligand binding to the receptor leads to the activation of the
guanylyl cyclase and results in a conformational change. The Cterminal guanylyl cyclase then comes into a tight association that
leads to conversion of guanosine triphospate (GTP) to 3´5´- cyclic
guanosine monophosphate (cGMP) (Chinkers & Wilson, 1992; Foster et
al., 1999). The ATP binding site in the kinase homology domain (KHD)
is believed to be essential for ligand-induced signal transduction and
12

deletion of the KHD depresses the guanylyl cyclase catalytic region
(Chinkers & Garbers, 1989). Phosphorylation of amino acid residues in
the KHD of the receptor is essential for normal function and
dephosphorylation appears to be one method of the natriuretic peptide
receptor desensitization (Potter & Garbers, 1992; Potter & Hunter,
1998).

Figure. 4. A model for natriuretic peptide receptor activation

Adapted from Silberbach and Roberts 2001
13

The end result of these mechanisms of receptor activation is
increased concentration of intracellular cGMP; cGMP in turn exerts its
physiological effects by binding to one of three cGMP binding proteins.
cGMP

dependent

protein

kinases

(PKG),

cGMP

binding

phosphodiesterases (PDE) and cyclic nucleotide gated ion channels
(Pfeifer et al., 1996; Rybalkin et al., 2003; Smolenski et al., 1998).
As mentioned earlier, natriuretic peptide receptor type-C (NPRC) has a short intracellular sequence that doesn’t have a guanylyl
cyclase domain. The major role of NPR-C was initially believed to be as
a clearance receptor and regulation of the plasma concentration of ANP
and BNP through receptor mediated internalization and degradation
(Matsukawa et al., 1999). However recent evidence suggests that
NPR-C is involved in signaling that leads to reduction of adenylyl
cyclase activity through activation of inhibitory G protein (Gi) (AnandSrivastava & Trachte, 1993; Rose & Giles, 2007).
The natriuretic peptides are cleared from the circulation by three
mechanisms. Endocystosis and degradation by coupling with NPR-C,
enzymatic cleavage by neutral endopetidases and by glomerular
filtration and excretion in the urine (Boerrigter & Burnett, 2004; Freda
& Francis, 2006).

14

Tissue Distribution of Natriuretic Peptides and their Receptors
The atrial and ventricular cardiomyocytes are the main sites of
production and storage of ANP and BNP, respectively. This was
confirmed through seminal experiments that showed that atrial
appendectomy resulted in marked reduction of both the plasma levels
of

ANP and the diuretic and natriuretic effect seen in response to a

volume load with isotonic saline (Veress & Sonnenberg, 1984;
Villarreal et al., 1986). Nevertheless, ANP and BNP mRNA have been
detected in several non-cardiac tissues including the adrenal glands,
the kidneys, lung, the gonads, lymphoid tissue and the gut (Gerbes et
al., 1994; Gower et al., 1994; Gower et al., 2003; Li et al., 2006;
Nguyen et al., 1990; Sharkey et al., 1991; Vollmar, 1990). Natriuretic
peptide receptors have also been detected in the gastrointestinal (GI)
tract of both non-mammalian and mammalian species including
humans (Gower & Skvorak, 1997; Li & Goy, 1993; Lowe et al., 1989;
Ohyama et al., 1992; Schulz et al., 1998).

Physiological Effects of the Natriuretic Peptides
Vascular relaxation is one of the most important physiological
actions of the natriuretic peptides. Binding of cGMP to PKG is known to
regulate ion channels in vascular smooth muscle cells with a cascade
of molecular events that culminate in a lower concentration of
15

intracellular calcium. These effects include reduction of calcium influx,
increase of calcium efflux and promotion of calcium sequestration in
sarcoplasmic reticulum (Tamaoki et al., 1997). Reduced vascular tone
and vasodilatation in turn results in lower total peripheral vascular
resistance

which

has

important

physiological

benefit

on

the

cardiovascular system; especially in the face of cardiac ischemia or
volume overload. Such vascular relaxation and vasodilatation will also
result in reduced pressure in the renal afferent arterioles thereby
increasing glomerular filtration, promoting diuresis and natriuresis. In
addition to these effects on vascular smooth muscle cells, the direct
effect of ANP and BNP on renal tubules and mesangial cells as well as
inhibition of the renin angiotensin aldosterone (RAAS) system results
in decreased sodium absorption from the renal tubules (Lohmeier et
al., 1995; Zeidel, 1993).
ANP and BNP are also known to decrease sympathetic outflow
and catecholamine release from peripheral sympathetic neurons which
benefits the cardiovascular system since it leads to lower blood
pressure, decreased heart rate and natriuresis (Levin et al., 1988).
Further support for the importance of the natriuretic peptides in blood
pressure and blood volume regulation comes from data showing that
NPR-A transgenic mice show chronic hypertension and ventricular
hypertrophy (John et al., 1995). NPR-A transgenic mice were recently
16

shown to have an upregulation of the angiotensin converting enzyme
(ACE) and angiotensin II type 1a receptor (AT1) mRNA by up to fourfold

signifying

the

importance

of

the

natriuretic

peptides

in

counteracting the effect of the renin angiotensin aldosterone (RAS)
system (Vellaichamy et al., 2007). It is also shown that NPR-A
knockout mice exhibit dysregulation of matrix metalloproteinases and
tissue inhibitors of metalloproteinases; enzymes involved in the
regulation of collagen synthesis and organization of myocardial fibrils
(Li et al., 2000; Spinale, 2002). As a result NPR-A knockout mice show
increased tendency towards myocardial fibrosis, hypertrophy and
eventually heart failure that leads to premature death as compared to
the wild type mice.

Gastrointestinal Effects of Natriuretic Peptides
Natriuretic peptides are known to have several effects on
contractile and absorptive functions in the GI tract. ANP has been
shown to inhibit intestinal sodium and water absorption in teleost and
mammalian intestines (Barros et al., 1990; Matsushita et al., 1991;
O'Grady et al., 1985). A decrease in jejunal water absorption in
response to intravascular volume overload was also shown in rats.
Such a decrease in transjejunal water absorption was absent in rats
that underwent right atrial appendectomy and this effect returned
17

when ANP was exogenously administered (Pettersson & Johnsson,
1989).

Intravenous administration of BNP and CNP has also been

shown to decrease jejunal electrolyte and water absorption in dogs
(Morita et al., 1992). Earlier investigations have also shown that
injection of either ANP or BNP into the cerebral ventricles inhibits thirst
induced by water deprivation or angiotensin (Antunes-Rodrigues et al.,
1985; Itoh et al., 1988; Zhu & Herbert, 1996). Furthermore, ANP and
BNP have been shown to have an indirect effect on uptake and
excretion of sodium and water through inhibition of vasopressin and
aldoseterone secretion (Januszewicz et al., 1986; Nguyen et al.,
1989).
The effect of natriuretic peptides on contractility of GI smooth
muscle has been documented beginning with the early discovery of
these peptides and their receptors in the GI tract (Scott & Maric,
1991). Subsequent studies have confirmed these findings showing that
ANP, BNP and CNP all inhibit contractility of isolated gastric and
intestinal

smooth

muscle

cells

from

different

species

including

humans(GuoCui et al., 2003; GuoJin et al., 2003; Yasuda et al.,
2000).
Apart from the traditional ‘cardiac’ natriuretic peptides ANP, BNP,
and CNP; the GI tract is also known to be a source of two peptides
with structures very similar to the natriuretic peptides. Guanylin and
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uroguanylin were first isolated from rat intestine and opossum urine
and later found to be widely distributed in non-mammalian and
mammalian species including humans (Beltowski, 2001; Date et al.,
1998).

In

humans,

uroguanylin

is

mainly

expressed

in

the

enterochromaaffin (EC) cells of the duodenum (where ANP is also
expressed), whereas

guanylin is expressed in the jejunum and the

colon (Beltowski, 2001; Li et al., 2006).

Uroguanylin is secreted in

response to oral salt load and the circulating hormone is known to
mediate sodium balance in the post-prandial state by increasing renal
excretion of sodium and potassium while the luminally secreted
hormone leads to increased chloride and bicarbonate secretion in to
the lumen of the intestine (Beltowski, 2001; Forte et al., 1996).
Uroguanylin and guanylin mRNA are detectable in the atrial and
ventricular myocardium and interestingly, plasma levels of guanylin
and uroguanylin are increased during heart failure and renal failure
(Beltowski, 2001; Forte et al., 1996). Both guanylin and uroguanylin
receptors are membrane bound guanylyl cyclase

enzymes and

activation of these receptors leads to increased intracellular cGMP
(Carrithers et al., 1999; Forte et al., 1996; Forte et al., 1999). Both
synergistic and antagonistic interaction between ANP and BNP on one
hand and uroguanylin and guanylin on the other have been shown and
there has been some suggestion that this evidence points to a
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probable regulatory link between the kidney and the GI tract in the
process of sodium and water balance (Santos-Neto et al., 2006).
Taken together, the remarkable genetic conservation of the
natriuretic peptides, the stimuli for their release and their effect on
sodium and water uptake is strong evidence that they serve crucial
physiological functions that conferred survival benefit earlier in
evolutionary times and have since evolved to be important conveyers
of signals among the various organ systems involved in cardiovascular
homeostasis.
While the cardio-renal link is now sufficiently well established,
there have been very few studies conducted to assess the functional
significance of the effect of natriuretic peptides on the GI tract and
how this all fits in the bigger scheme of volume regulation. The early
observations on the effect of natriuretic peptides as well as recent
evidence showing the presence and role of a possible ‘intestinal’
natriuretic peptide system raise several intriguing questions. If the
heart sends humoral signals to the kidney to decrease sodium
absorption, shouldn’t it also use the same signals to limit sodium and
water absorption from the GI tract? GI symptoms such as nausea,
indigestion and malabsorption are frequent clinical findings in the face
of acute heart attack or chronic heart failure, states where BNP levels
are elevated. Could BNP be responsible for some of these symptoms?
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If so, could there be potential targets of therapy for heart failure in the
GI tract?
Our studies will provide evidence that the effect of natriuretic
peptides on gastric and intestinal smooth muscle cell contractility has a
functional dimension. By directly testing the effect of ANP, BNP and
CNP on gastric contractility, gastric emptying and absorption we show
that these peptides do decrease gastric emptying and absorption.
Moreover BNP, a peptide with increasing clinical utility, is shown here
to

cause

decreased

gastric

emptying

and

intestinal

absorption

following acute myocardial injury using a whole animal cryo induced
acute MI model. While our data suggests that these effects may be
mediated by NPR-A, we also show data that suggests a more direct
effect on absorptive structures at the level of intestinal microvilli.
Further characterization of the signals involved in these functions not
only adds a new dimension to cardiovascular research but could also
lead to identification of new therapeutic targets for the treatment of
heart failure.
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CHAPTER TWO
MATERIALS AND METHODS
Measurement of Gastric Contractility and Intragastric Pressure
These protocols were approved by the University of South Florida
Institutional Animal Care and Use Committee.

Experimental Animals
NPR-A Knockout (KO) mice were obtained from our resident
colony that was founded with pathogen-free breeding pairs and were
genetically monitored by PCR of tail-snip DNA. The generation of NPRA knockout mice has previously been described in detail (Lopez et al.,
1995). Wild type (C57BL/6) mice were purchased from commercial
sources. The wild type (WT) mice were all males with ages ranging
from 8 to 12 weeks and weight ranging from 18-26 grams at the time
of the experiment. The NPR-A KO mice ranged from 10 to 32 weeks in
age and 24-38 grams in weight at the time of the experiment, with
equal number of male and female KO mice in the experiment and
vehicle group. The parental strain of the knockout mice was C57BL/6.
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Surgical Preparation
In order to objectively determine the effect of natriuretic
peptides on gastric contractility, a method of measuring intragastric
pressure before and after peptide injection was developed as follows.
The mice were anesthetized with sodium pentobarbital (0.9 mg/10 gm
body weight) given intraperitoneally (ip) and supplemental doses of
0.5 mg given ip as needed. The mice were then placed on a
temperature

controlled

surgical

table

and

a

tracheotomy

was

performed using a 20 ga. Luer-stub adapter. The right jugular vein
was catheterized with polyethylene (PE)10 tubing for injections and
infusions and the right carotid was catheterized with a 5 cm piece of
PE tubing (o.d. 0.012”, i.d. 0.006”: Braintree Scientific, Inc.) attached
to a 12-18” segment of PE 50 tubing for arterial blood pressure
measurements.

A 10 mm left sub-costal skin incision was made to

access the stomach. A 3 mm vertical incision of the stomach fundus
was made with cautery carefully choosing a site that has minimal or no
visible blood vessels. A 2-3 mm latex balloon fitted with PE tubing and
primed with saline was inserted into the stomach. The balloon was
then minimally distended by adding 20-25 µl of saline and attached to
a

standard

pressure

transducer

(Gould/Statham

DB25).

The

intragastric catheter was held in place by the minimal distension of the
balloon and suturing the stomach incision was not necessary. The skin
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incision was closed with 1-2 interrupted surgical sutures. Following
these surgical preparations, the mice received a 100 µl bolus of 0.9%
saline intravenously (iv) via the jugular catheter and then allowed a
one hour equilibration period while being infused with 0.9 % saline iv
at 5 µl/minute. The saline bolus and infusion were administered to
compensate for blood loss associated with the surgical procedure and
maintenance fluid requirement. Arterial blood pressure, heart rate and
intragastric pressure were monitored continuously via the carotid and
intragastric catheters and recorded on a data acquisition system
(DATAQ Instruments, Akron, OH).
The change in intragastric pressure was measured as the
difference

between

the

peak

and

baseline

pressure.

The

measurements were taken for three 30 minute periods. The basal
gastric pressure was measured from 30 to 0 minutes before injection.
Post injection period was from 10 to 40 minutes after injection to
correspond with the peak plasma level of the peptides and the
recovery

period

was

from

90

to

120

minutes

after

injection

corresponding to the period later than 5 peptide half-lives (12). The
changes in intragastric pressure during each of the three periods were
averaged for each mouse and the differences in intragastric pressure
between the experimental and vehicle groups during the three periods
were compared using a one way ANOVA with Fisher’s least significant
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difference test (LSD) used as a post hoc test. A “p” value of <0.05 was
considered the criteria for statistical significance.

Positive and Negative Controls
Gherelin, a hormone with known prokinetic gastrointestinal
effect in rodents, was used as a positive control to ascertain that the
waves of contraction we observed and recorded were indeed changes
in gastric motility (Depoortere et al., 2005). Gherelin (Rat, Phoenix
pharmaceuticals, C# 031-31, Lot # 423341) was administered at a
dose of 50 µg/kg body weight in 100 µl of vehicle iv, a dose previously
established to increase gastric motility in rodents.
The vehicle was used as a negative control. The vehicle
consisted of modified Krebs-Hensledt bicarbonate buffer equilibrated
final PH = 7.4, dissolved in the order shown in table 1.
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Table 1. Composition of modified Kreb’s solution (g/l)

CaCl2

0.220g

MgSO4

0.144g

KCl

0.224g

KH2PO4

0.163g

NaCl

6.72g

NaHCO3

2.1g

Glucose

1g

Albumin

1g
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Table 2. Millimolar concentration of modified Kreb’s solution

Na+

140

K+

4.2

Ca2+

1.5

Cl-

123

Mg2+

1.2

HCO3

25

H2PO4

1.2

SO4

1.2

Glucose

2.5

Albumin

0.1%

(BSA fraction V)

27

Blood Pressure Measurement
Mean arterial pressure was continuously monitored using an
intra-carotid catheter and recorded. Average blood pressure was
measured for the same three periods as for the gastric pressure
measurement. Pre vs. post peptide injection blood pressures were
compared to ascertain that our findings were not confounded by
differences in blood pressure.
Measurement of Gastric Emptying
Conscious WT and NPR-A KO mice (n = 5 in each group) were
given BNP at dose of 10 ng/g through the tail vein dissolved in 100 µl
of vehicle (modified Krebs solution) or the vehicle alone and
immediately gavaged with 0.1 ml of 0.5 Mmol 70 kDa fluoresceinisothiocyanate (FITC)-dextran. The 70 kDa FITC-dextran is known to
be

non-diffusible

across

intestinal

membrane

thus

suitable

for

measurement of emptying (Thorball, 1981). Thirty minutes after the
gavage meal, the animals were euthanized and the stomach was
separated and the intestine divided into 8 equal segments, each
flushed with 3 ml of PBS and centrifuged for 10 minutes. Fluorescence
of the supernatant fluid was measured and the percent gastric
emptying rate was compared in BNP treated vs. control for both WT
and NPR-A KO mice. This method of evaluating gastric emptying has
been previously established (Aube et al., 2006).
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Measurement of Absorption
Conscious WT & NPR-A KO mice (n = 5 in each group) were
given 10 ng/g of BNP through the tail vein dissolved in 100 µl of
vehicle (modified Krebs solution) or the vehicle alone. The mice were
then gavaged with 0.01 ml/g of a solution containing 22 mg/ml of 4
kDa FITC-dextran. Blood was collected via cardiac puncture under
pentobarbital anesthesia. Fluorescence was quantified using relative
fluorescence units in the plasma. The plasma fluorescence measured 1
hour after gavage feeding in WT and NPR-A KO mice was compared for
BNP treated vs. control. Similar comparisons were made for the
subsequent experiments between sham vs. Mi in both WT and NPR-A
KO mice. The group differences were analyzed using a t-test with
p<0.05 considered the significant level for statistical difference. This
method

of

evaluating

gastric

absorption

has

been

previously

established (Aube et al., 2006).
We also compared the fluorescence of a 50 µl plasma sample
taken 1 hour after iv administration of 100 µl of 0.5 mmol 4kDa FITCdextran in BNP treated vs. vehicle WT mice. The purpose of this test
was to rule out the possibility that the changes in plasma fluorescence
were produced by other actions of BNP such as increased excretion,
redistribution or metabolism of the dextran as this effect of BNP has
been previously established (Huxley et al., 1987).
29

The concentration of fluorescein was determined using a
fluorimeter (FLUOstar Galaxy, BMG Labtechnologies) with an excitation
wavelength at 485 nm and an emission wavelength of 520 nm using
serially diluted samples of the marker as standard.

Table 3. Peptides used in this study

ANP

Rat ANP, Sigma, P # A8208

BNP

Rat BNP-32, Phoenix Pharmaceuticals, 011-14,
Lot # 421752

CNP
c-ANF

Rat 32-53, Bachem, P # H-1296, Lot # B00656
4-23

Gherelin

Rat, Phoenix Pharmaceuticals
Rat, Phoenix Pharmaceuticals, C # 031-31, Lot # 423341

In the initial experiments, the peptides were administered
intravenously at 10 ng/g body weight. This dose was chosen to raise
and sustain the plasma levels above 500 pg/ml; a level that is
consistent with a greater than 90% likelihood of heart failure (for BNP)
in humans (Maisel & Mehra, 2005).

For subsequent dose response

experiments we administered BNP at 1, 5, 10 and 100 ng/g body
weight iv.
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Induction of Myocardial Ischemia (Myocardial Injury)
Wild-type and NPR-A knockout mice were anesthetized with 23% isoflurane-oxygen flow at 500ml/minute. A 2 mm incision was
made through the skin, just distal to the 4th and 5th intercostal space.
Blunt dissection through all thoracic musculature, using a fine-tipped
instrument was performed to accommodate passage of a probe
induction catheter (PIC).

Using digital pressure, the distal tip of the

PIC (catheter cap in place) was flattened as much as possible (to aid in
atraumatic insertion), and the PIC was then passed through the
muscle wall.

Prior to removing the cap, the operator pinched the

proximal

of

tip

the

PIC

shut

(to

aid

in

the

prevention

of

pneumothorax). The oxygen flow was then turned up to 2 L/min. The
liquid-nitrogen-cooled probe was then quickly threaded through the
PIC, to the full length of the PIC. If needed, the PIC was then gently
repositioned so the bevel and the cooled probe were in direct contact
with the left ventricle of the heart. Correct placement of the probe,
with subsequent cardiac thermal injury, was confirmed as the super
cooled probe "grabbed" the warmer tissue of the heart, and remained
affixed until the probe had warmed enough for release. After passive
release, the probe and PIC, as one unit, were quickly withdrawn and
the ribs were then immediately brought into apposition. A pre-loaded
1/2 cc syringe of tissue glue (VetBond™) was then used for closure.
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The experiment to study emptying and absorption were performed at 1
and 2 weeks after this surgical procedure (cryo induced myocardial
injury/infarction).
Plasma BNP Measurement by Radioimmunoassay
Plasma BNP levels were measured by radioimmunoassay (RIA).
(Peninsula Laboratories, 5-2104 RIAS 9085). The assay is based upon
the

competition

of

125

I-labeled

peptide

and

unlabeled

peptide

(unknown sample) binding to the limited quantity of antibodies specific
for peptide in each reaction mixture. As the quantity of peptide in the
unknown sample in the reaction increases, the amount of

125

I-bound

peptide able to bind to the antibody is decreased. By measuring the
amount of
peptide

125

in

I- bound peptide as a function of the concentration of the

standard

reaction

mixtures,

a

“standard

curve”

is

constructed from which the concentration of peptide in the unknown
sample can be determined.
The summary of the assay protocol is as follows:
1- A 100 µl of unknown sample is pipetted in to duplicates glass
test tubes
2- 100 µl primary antibody is added to unknown samples,
vortexed, and incubated overnight at 4°C.
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3- 100 µl of the I

125

labeled peptide is added and incubated

overnight at 4°C.
4- Goat rabbit antiserum and normal rabbit serum is added and
vortexed at 4°C and incubated for 90 minutes
5- 500 µl of RIA buffer is added, vortexed and centrifuged at
1700 x g for 20 minutes
6-The supernatant is aspirated off except in the total counts
tube
7- Use gamma counter to count the level of radioactivity
8- The data obtained from the gamma counter is analyzed using
the program Assayzap, Biosoft, GB, United Kingdom.
The detailed assay protocol is found in the product insert for the assay
kit (Phoenix pharmaceuticals, C# RK-011-17)
The kit we used has a cross reactivity of 41% with the mouse
BNP and total binding of 46%; calculations were made accordingly.
The detection range for this kit was 10-128 pg/ml.

Immunostaining for Non-Muscle Myosins
Two WT mice were given a bolus of BNP at 10 ng/g body weight
in 100 µl of modified Kreb’s solution followed by infusion of BNP at 1
ng/g for 30 minutes. One WT mouse was given 100 µl of vehicle and
given an infusion of vehicle for 30 minutes
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1-

The animals were then euthanized and intestinal tissue collected
and

sectioned

into duodenum,

jejunum,

ileum

and colon

following anatomical demarcations.
2-

The tissue is fixed in 4% paraformaldehyde over-night at 4°C.

3-

The next morning the tissue is washed with phosphate buffered
saline (PBS) for 15 minutes twice at room temperature with
gentle rocking.

4-

After the wash, the tissue is dehydrated and permeabilized as
follows. Tissue is placed in ascending concentration of 30, 50
and 70 % methanol each for 15 minutes. Then the tissue is
placed in a solution composed of 100 % methanol: DMSO: 30%
H2O2 made at a ratio of 4:1:1. The tissue is left in this solution
overnight at 4°C .

5-

The next morning the tissue is washed in 70 % methanol for 30
minutes at room temperature with rocking.

6-

Rehydration is accomplished by serially placing the tissue in 70
% methanol/PBS for 30 minutes with rocking, then 50 % of
methanol/PBS with rocking, then 1 ml of PBS for 30 minutes
with rocking, 1 ml of PBSMT (PBS, milk, Tween 20) 30 minutes
with rocking twice.

7-

The tissue is then incubated overnight with 1 ml of primary
antibody diluted in PBSMT (1:250) with rocking at 4 °C.
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8-

The next morning the tissue is rinsed with PBSMT 2x with 1 ml
for 1 hour at 4°C, 4 x in 1 ml for 1 hour each at room
temperature.

9-

Next the tissue is incubated overnight with 1 ml of the
Secondary antibody diluted in PBSMT (1:250) at 4°C while
rocking.

10- Next morning the tissue is washed as above with PBSMT
11- Next tissue is rinsed with PBT (PBS and Tween -20 equal
concentration).
12- Post fixing in 4 % paraformaldehyde in PBS at 4 ° C overnight.
13- Dehydration in the following sequence, 1 ml of PBT quick rinse, 1
ml PBT for 30 minutes at room temperature, 1 ml 50 %
methanol for 30 minutes, 1 ml of 70 % methanol for 30 minutes
at room temperature; 1 ml of 100 % methanol 30 minutes at
room temperature twice.
14- Plastic embedding is achieved by transferring the tissue from
100 % methanol to araldite embedding medium and kept in
medium for 3 hours. The tissue is then transferred into a fresh
embedding medium into a mold on araldite rafts and the mold is
kept overnight in 60° C oven to allow the araldite to harden.
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15- The hardened plastic embedded tissue is then trimmed and
sectioned using a microtome at 1-3 µm thickness. The sections
pass automatically into water, the sections are transferred onto
a slide and allowed to dry for 5-10 minutes on the surface of a
hot plate. The first and last section are placed on one side and
stained with toluidine blue to guide orientation.

Details of the above technique are found in (Linask & Tsuda, 2000).

Statistical Methods
We used a one way analysis of variance (ANOVA) to compare the
average intragastric pressure at baseline, immediately after and later
than five peptide half-lives after peptide injections. Fisher’s least
significant difference (LSD) test is used as a post hoc test.
Two sample t-tests were used to compare the measures of gastric
emptying and absorption between peptide treated vs. vehicle treated
mice. Specifically percent gastric emptying between treated vs. vehicle
and average relative fluorescence units between the peptide treated
vs. vehicle groups were tested using a two sample t-test.
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CHAPTER THREE
THE EFFECT OF NATRIURETIC PEPTIDES ON INTRAGASTRIC
PRESSURE, GASTRIC EMPTYING AND ABSOPRTION
INTRODUCTION
Measurement of gastric pressure using an intragastric balloon
(manometry) offers the most direct way to quantify pressure changes
inside the stomach (Malagelada & Stanghellini, 1985; Mearin &
Malagelada, 1993). Other factors being constant, the measured gastric
pressure is directly proportional to the force of contraction of the
stomach wall (Mearin & Malagelada, 1993); therefore quantifying and
comparing the rate of change in pressure between experimental
groups yields a reliable and objective measure of gastric contractility.
However, due to the inherent variability of baseline pressure among
different animals, we further standardized the measurement by using
the difference between the baseline and peak of the gastric contraction
wave in our analysis. This makes our measurement less prone to
variability and a more objective way to compare differences in
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pressure between or among different groups of animals in these
experiments.
Our measurements of gastric emptying and absorption were
designed to be as close to the physiological state as possible. We used
gavage feeding of fluorescence labeled dextran and let the mice roam
freely for 30 minutes, following which the surgery was performed and
measurement taken. The 70 kDa FITC-dextran was shown to be a
valid measure of emptying in prior studies as was the 4 kDa FITC
dextran for gastrointetsinal absorption (Aube et al., 2006; Thorball,
1981). Since there is a theoretic possibility that there is a potential
confounding by the action of BNP on arterial permeability and
distribution of the dextran to the third space (rather than GI tract
permeability or absorption) we measured and compared plasma
fluorescence after intravenous injection of 4 kDa FITC-dextran in BNP
treated and control animals. This avoids the potential confounding and
validates our measurement.
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RESULTS

Intragastric Pressure and Gastric Contractility
A typical intragastric pressure wave pattern is shown in figure 5;
gastric contraction frequency averaged 3-7 times per minute ranging
from 0.5 to 10 mmHg in amplitude.

Figure 5. Typical pressure wave pattern of a basal gastric
contraction

A recording of a basal pressure pattern in windaq file is shown above.
Division width = 4 seconds and division height =1 mmHg. Recording
shown is a 10x compression (approximately 3 minutes) view of an
actual experiment
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Figure 6. Simultaneous recording of blood pressure
and intragastric pressure

Two channel recording in our data acquisition system - windaq, Top
panel shows blood pressure and bottom panel shows intragastric
pressure. Note; division heights are 6.25 mmHg in top panel and 1
mmHg in bottom panel. Division width is 4 seconds in both channels.
Recording shown is 10x compression of an actual experiment.
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The prokinetic agent gherelin was used to ascertain that these
recordings from the intragastric balloon corresponded to changes in
gastric motility. Administration of gherelin resulted in a marked and
significant increase in intragastric balloon pressure, validating that the
contraction waves recorded are that of changes in gastric contractility.
Gherelin was administered in three experiments and a typical response
is shown in figure 7.

Figure 7. The effect of intravenous administration of Gherelin
on intragastric pressure

Davison width = 8 seconds and division height = 1mmHg.
Arrow indicates point of injection of gherelin
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Figure 8. Three individual experiments showing intragastric
pressure after a 10 ng/g iv bolus of ANP, BNP and CNP.
A
N
P

B
N
P

C
N
P

Division height = 1mmHg. Division width = 300 seconds
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As shown in figure 8, intragastric pressure was decreased after
injection of any of the three natriuretic peptides, ANP, BNP or CNP and
the pressure gradually returned towards the baseline values.
Figure 9. Typical recording of post peptide injection gastric
contraction wave pattern

Gastric pressure was attenuated after injection of BNP without
significant change in frequency of contraction. Also seen is a slight dip
in mean arterial pressure following BNP injection. Arrow indicates point
of injection. ‘Decompressed’ view, image shown is approximately 1
minute. A similar effect was observed for ANP and CNP.
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Figure 10. The effect of C-ANP4-23 on gastric pressure

Individual experiment showing no change in gastric pressure or blood
pressure when the specific NPR-C ligand cANP4-23 was injected in to
wild type mice at 10 ng/g body weight iv.
Division width =80 seconds
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Figure 11. BNP did not change gastric pressure in NPR-A knock
out mice

NPR-A knock out mice did not show decreased intragastric pressure
with any of the natriuretic peptides. Here BNP was administered at 10
ng/g body weight iv.
We quantified the change in intragastric pressure by averaging the
difference between the peak and baseline gastric pressures for three
thirty minute periods; before, immediately after and later than 5
peptide half-lives after peptide injection.
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Figure 12. Determination of baseline and peak intragastric
pressure before and after peptide injection

Since each experimental animal had different baselines; comparing the
difference between baseline and peak (i.e., the change in amplitude of
the gastric contraction wave) was found to be more precise and
reliably comparable among different experimental animals. The basal
pressure was defined as the lowest pressure immediately before a
peak and the peak was determined by moving the cursor and
recording the highest point of the peak pressure.
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Figure 13 (below) shows the pooled data on comparison of the
average gastric pressure before peptide injection (Basal), immediately
following peptide injection and later than 5 BNP half-lives (Recovery)
vs.

vehicle.

As

shown,

BNP

significantly

decreased

intragastric

pressure from a basal value of 2.26 ± 0.29 mmHg to 1.44 ± 0.11
mmHg and gastric pressure returned to 2.08 ± 0.17 mmHg when
measured later than 5 BNP half-lives (n=5, p<0.05, ANOVA, Fisher’s
LSD test). Similar and statistically significant reduction of gastric
pressure was obtained for ANP and CNP (Figures 14 and 15). ANP
significantly decreased gastric pressure from a basal value of 2.11 ±
0.3 mmHg to 0.7 ± 0.25 mmHg and CNP decreased gastric pressure
from a basal value of 1.91 ± 0.3 mmHg to 0.85 ± 0.24 mmHg.
Average gastric contractions per minute were 4.4 ± 0.7, 3.1 ± 0.4 and
4.3 ± 0.5 for periods of BNP injection compared to 5.3 ± 1.2, 4.2 ±
0.6 and 4.3 ± 0.5 for the vehicle group (all p>0.05, ANOVA).There
was no difference in gastric pressure in BNP treated vs. vehicle treated
NPR-A KO mice.
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Figure 13. Mean reduction in intragastric pressure following
intravenous BNP injection

Intragastric Pressure
(mmHg)

4
BNP
Control

3
2

*
1
0
Basal

Post injection Recovery

Mean reduction in intragastric pressure (measured in mmHg) following
intravenous BNP 10 ng/g in 100 µl of vehicle vs. 100 µl of vehicle
injection to WT mice (n = 5 in each group). Intragastric pressure
measured before (Basal), immediately after (Post Injection) and more
than 5 peptide half-lives after injection (Recovery) is shown.
BNP significantly (* = p < 0.05, ANOVA, Fisher’s LSD test) decreased
intragastric pressure compared to vehicle. Gastric pressure returned
toward basal levels when measured later than 5 BNP half-lives.
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Figure 14. Mean reduction in intragastric pressure following
intravenous ANP given at a dose of 10 ng/g body weight

Intragastric Pressure
(mmHg)

4
ANP
Control

3

2

*

1

0
Basal

Post injection Recovery

Mean reduction in intragastric pressure (measured in mmHg) following
intravenous ANP 10 ng/g in 100 µl of vehicle vs. 100 µl of vehicle
injection to WT mice (n = 5 in each group). Intragastric pressure
measured before (Basal), immediately after (Post Injection) and more
than 5 peptide half-lives after injection (Recovery) is shown.
ANP significantly (* = p < 0.05, ANOVA, Fisher’s LSD test) decreased
intragastric pressure compared to vehicle. Gastric pressure returned
toward basal levels when measured later than 5 ANP half-lives.
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Figure 15. Mean reduction in intragastric pressure following
intravenous CNP given at a dose of 10 ng/g body weight

Intragastric Pressure
(mmHg)

4
CNP
Control

3

2

*

1

0
Basal

Post injection Recovery

Mean reduction in intragastric pressure (measured in mmHg) following
intravenous CNP 10 ng/g in 100 µl of vehicle vs. 100 µl of vehicle
injection to WT mice (n = 5 in each group). Intragastric pressure
measured before (Basal), immediately after (Post Injection) and more
than 5 peptide half-lives after injection (Recovery) is shown.
CNP significantly (* = p < 0.05, ANOVA, Fisher’s LSD test) decreased
intragastric pressure compared to vehicle. Gastric pressure returned
toward basal levels when measured later than 5 CNP half-lives.
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Gastric Emptying
Gastric emptying was measured by gavage feeding a 0.1 ml of
2.5 mmol 70 kDa FITC labeled dextran to conscious mice immediately
after a 10 ng/g body weight bolus of BNP. The mice were sacrificed 30
minutes after gavage and the amount of fluoresce that has emptied
the stomach as a percent of total fluorescence measured in the entire
GI tract was calculated and compared between the BNP treated vs.
vehicle treated mice.
Figure 16. The effect of BNP on gastric emptying

90

*

80

70

60

Vehicle

NPR-A Knockout
Percent Gastric Emptying

Percent Gastric Emptying

Wild Type
100

100

90

80

70

60

Vehicle

BNP

BNP

Percent gastric emptying, measured in amount of fluorescence that
emptied the stomach as a percentage of the total fluorescence
measured in the entire gastrointestinal tract 30 minutes after gavage
feeding of 0.01 ml of 2.5 mmol 70 kDa FITC-dextran.
BNP (10 ng/g iv) significantly decreased gastric emptying in wild
type mice compared to vehicle (n =5, p < 0.05, t-test,). This effect of
BNP was absent in NPR-A knockout mice (n = 5, p > 0.05, t-test).
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Percent Gastric Emptying

Figure 17. Dose dependent reduction of gastric emptying
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*
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60
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Vehicle 5 ng/g

10 ng/g 100 ng/g

Figure 17 shows percent decrease in gastric emptying as a
function of BNP dose in WT mice. Measurements were taken 30
minutes after gavage feeding of 0.01 ml/g of 2.5 mmol FITC-dextran.
Progressive doses of BNP at 5, 10 and 100 ng/g iv resulted in
significant reduction of gastric emptying. (p < 0.05, n = 4 in each
group, ANOVA, Fisher’s LSD test)
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Absorption
To measure absorption we used gavage feeding of 22ml/kg of a
solution containing 22mg/ml 4 kDa FITC-dextran to conscious mice
immediately following a 10 ng/g dose of BNP vs. vehicle. The plasma
fluoresce (taken 1 hour after gavage) was measured and compared
between the two groups. Plasma fluorescence after iv injection of FITC
dextran is also measured and shown below to ascertain that the
difference was not due to distribution rather than absorption.
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Relative Plasma Fluorescence

Relative Plasma Fluorescence

Figure 18. The effect of BNP on absorption
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Absorption measured in relative plasma fluorescence units one hour
after gavage feeding of 4 kDa FITC-dextran in wild type mice BNP
treated (10 ng/g iv) vs. vehicle (n = 5, p < 0.05, t-test). No significant
difference in absorption was observed between BNP vs. vehicle treated
NPR-A KO mice (p > 0.05).
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Figure 19. Plasma fluorescence following intravenous

Relative Plasma Fluorescnce

FITC- dextran, BNP vs. Vehicle
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Relative fluorescence of a 50µl plasma sample taken 1 hour after
intravenous administration of 100 µl 0.5mmol 4kDa FITC-dextran is
shown. BNP treated (10 ng/g iv) vs. vehicle in wild type mice, (p >
0.05, n = 4 in each groups, t-test).
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Mean arterial blood pressure was continuously monitored during
all experiments using an intra-carotid catheter. There was a slight
reduction of average blood pressure from 62.9 ± 4.7 mmHg prior to
BNP injection to 59 ± 3.2 mmHg (n=5, p>0.05, ANOVA, Fisher’s LSD
test). Blood pressure returned to 61.4 ± 5.08 mmHg when measured
later than 5 peptide half-lives.
Similar drops in blood pressure were also observed during the
first few minutes after injection of both ANP and CNP with return of
blood pressure towards baseline.
Plasma BNP levels averaged 4500 pg/ml and the levels fell to
725 pg/ml at 30 minutes post injection and to undetectable levels at
90 minutes post injection.
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DISCUSSION
These experiments show that the natriuretic peptides tested,
namely ANP, BNP and CNP all decreases intragastric pressure (gastric
contractility) in anesthetized mice. Prior studies have shown that
natriuretic peptides decrease contractility of isolated gastric and
intestinal smooth muscle cells in vitro (GuoCui et al., 2003; Yasuda et
al., 2000), this study is the first to show this effect to be true in the
whole intact animal. Furthermore, the inhibitory effects of the
natriuretic peptides appears to be dose dependent and mediated
primarily by NPR-A.
We further investigated whether this effect on contractility has a
functional significance in the whole animal. To accomplish this we
focused the subsequent studies on the effect of BNP on gastric
emptying and absorption; with its increasing utility in the diagnosis
and treatment of heart failure, further characterization of an aspect of
BNP is deemed to be potentially of important translational benefit.
Our findings confirmed that this effect of BNP on contractility is
accompanied

by

significant

reduction

in

gastric

emptying

and

gastrointestinal absorption; clearly demonstrating that this inhibitory
effect on the gastrointestinal tract has functional significance in the
whole animal.
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As shown in Figure 19, plasma fluorescence one hour after iv
administration of 4 kDa FITC-dextran was similar in BNP treated vs.
vehicle. This finding further strengthens our conclusion that the
reduced plasma fluorescence in gavage fed and BNP treated mice was
indeed due to decreased absorption or permeability in the GI tract and
not due to other known actions of BNP such as increased renal
excretion or change in vascular redistribution (Huxley et al., 1987).
Although there has been some indication that natriuretic
peptides are involved in inhibitory regulation of GI function (Ebert,
1988; Olsson & Holmgren, 2001), our findings are the first to
document a specific inhibitory role for BNP on emptying and absorptive
functions in the GI tract.
The average plasma BNP levels immediately after injection
averaged 4500 pg/ml. While this level is supra-physiological, it is not
uncommon in patients with heart failure (Fitzgerald et al., 2005).
Furthermore, even much higher levels of BNP are consistently seen
when recombinant BNP (Nesiritide) is administered for the treatment
of heart failure (Colucci et al., 2000). Moreover, the BNP level in our
experiments fell to levels routinely seen in heart failure patients at 30
minutes post injection. Therefore, our experimental model provides
novel insight into what would be expected in heart failure or when BNP
is exogenously administered.
57

Natriuretic peptides bind to transmembrane receptors that have
guanylyl cyclase (GC) activity. ANP and BNP bind to NPR-A where as
CNP binds to NPR-B. The ensuing peptide receptor interaction
increases intracellular cGMP with subsequent enzymatic steps that
regulate cellular functions in various tissues where these peptides
and/or receptors are expressed (Kuhn, 2005).
In our study, NPR-A KO mice did not show a significant response
with any of the peptides we used (ANP, BNP, CNP or c-ANP4-23). This
suggests that; the gastrointestinal effects of BNP and the other
natriuretic peptides are likely to be specifically mediated by the NPR-A
receptor.

Since

c-ANP4-23

specifically

binds

to

NPR-C

(Anand-

Srivastava, 2005), the absence of a GI effect when c-ANP4-23 was
injected into WT or NPR-A KO mice is additional evidence that NPR-A
may be the major receptor mediating the effect of BNP on gastric
emptying and absorption. Our finding is consistent with previous
studies that have shown that the inhibitory effect of CNP on isolated
gastric smooth muscle cells is mediated by a cGMP-dependent
pathway (GuoCai et al., 2003; Scotland et al., 2005).
The natriuretic peptides in general are among some of the most
evolutionarily

conserved

peptides

across

many

species

of

the

phylogenetic tree with various functions in fluid homeostasis. Studies
done early in the discovery of natriuretic peptides have reported that
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ANP significantly decreased jejunal fluid absorption in dogs and rats
(Morita et al., 1992; Scott & Maric, 1991). More recent studies have
shown that natriuretic peptides cause upregulation of aquaporin 3
expressions in human colonic epithelia signifying their potential role in
fluid homeostasis (Pacha, 2000). ANP has also been shown to be
important in promoting sea water adaptation in eels and decreases
intestinal sodium absorption (Tsukada et al., 2005). However, the
great majority of recent studies done on BNP have focused on its role
in modulating blood pressure, diuresis and natriuresis. Since the
primary stimulus for release of ANP and BNP is mechanical stretch of
the atrial and ventricular myocardium, their expression and release is
closely linked to body fluid volume status (Cowie & Mendez, 2002;
James et al., 2005). Moreover, the temporal pattern of expression and
release of BNP following a given stimulus, such as an acute myocardial
infarction, indicates that the endocrine heart could potentially employ
varying plasma levels of the natriuretic peptides to modulate body
fluid volume (Silver, 2006). Since natriuretic peptide receptors are
expressed on the gastric and intestinal smooth muscle cells, and we
show that intravenously administered BNP decreased gastric emptying
and absorption, it is logical to deduce that our finding may be an
indication that the endocrine heart employs natriuretic peptides to
delay or modulate the rate and amount of water and solute absorption
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from the gastrointetsinal tract. From a physiological stand point the
effect of cardiac hormones on absorption in the GI tract is a beneficial
extension of their role in volume homeostasis. Theoretically, such a
role could extend to pathophysiological states such as heart failure
where plasma BNP levels and volume overload progressively rise
(Barclay et al., 2006) and modulation of volume status becomes even
more critical for survival.
We have shown that high plasma levels of BNP (sustained levels
of 500 pg/ml or greater), significantly decrease gastric motility,
emptying and absorption in mice. This appears to be a common effect
of the natriuretic peptides shared by ANP and CNP. The absence of this
GI effect in receptor knockout mice and the dose-response relationship
suggests a receptor mediated specific event.
While our study in the mouse model can not be generalized to
humans, our findings that BNP significantly decreased gastric emptying
and absorption offers valuable new insights into the role of the
gastrointestinal tract in fluid homeostasis, especially during heart
failure. First, symptoms of perturbed gastrointestinal function such as
nausea, dyspepsia, indigestion and malabsorption are frequently seen
in patients with heart failure where plasma BNP levels are markedly
elevated (Krack et al., 2005; Shamsham & Mitchell, 2000). Our study
suggests that some of these symptoms could at least partly be
60

attributable to the elevated BNP. Secondly, such an effect by BNP
could potentially add a new area of interest and investigation in the
role of the heart as an endocrine organ. While there are established
physiological and pathophysiological cardio-renal regulatory pathways;
a possible ‘cardio-gastric and/or cardio-intestinal’ link via natriuretic
peptides appears to be another possible pathway involving the
endocrine heart.
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CHAPTER FOUR
THE ROLE OF BNP IN THE GASTRROINETESINAL
MANIFESTATION OF MYOCARDIAL INJURY

INTRODCUTION
Prior studies have utilized myocardial injury models to
study pathophysiological and histological effects exerted by the
natriuretic peptides on the cardiovascular system. Based on the results
of our experiments reported in the earlier chapters, mainly the fact
that the natriuretic peptides in general and BNP in particular decrease
gastric emptying and absorption; we postulated that these peptides
would have a similar effect in the face of acute myocardial infarction.
The most commonly used methods of inducing experimental
ischemia or myocardial infarction (MI) in mice are the permanent
ligation of left anterior descending (LAD) coronary artery and the
Cryoinfarction (freeze-thaw) method. In LAD ligation, the artery is tied
with surgical sutures whereas in cryoinfarction a blunt frozen metallic
probe is directly applied to a specific area of the myocardium with
resulting thermal ischemia at the point of contact and surrounding
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myocardium. Although the cryoinfarction method was introduced as
early as 1948 (Hass & Taylor, 1948) it is only recently that it is shown
to have several advantages over LAD ligation; as the LAD method is
associated with marked variability in the size of the infarct and leads
to apical infarct resulting in ventricular aneurysm (van den Bos et al.,
2005). In the cryoinjury model the infarct area is limited to the
anterior wall of the myocardium more closely resembling what is
encountered in clinical practice in humans; where reperfusion therapy
results in limited infarct size and chances of developing apical
aneurysm are becoming increasingly less likely (Huwer et al., 1998;
Roell et al., 2002; van den Bos et al., 2005). Pathophysiologically, The
cryoinfarction method causes acute cell death probably from the
mechanical process associated with thermal injury; the infarct border
therefore corresponds to the size of the probe hence the improved
consistency of the resulting infarction as compared to the LAD ligation
method (van den Bos et al., 2005). Moreover since the cryoinfarction
method has a much lower peri and post operative mortality, fewer
numbers of animals will be needed for a given study.
We used a cryoinfarction model as the degree and distribution of
the infarct (Cell death and fibrosis) is more consistent with the
cryoinfarction as compared to the Left anterior descending artery
(LAD) ligation method (Huwer et al., 1998; Roell et al., 2002).
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This study was designed to test whether a cryoinfarction of the
myocardium leads to change in gastric emptying and absorption in
mice and whether the difference in the plasma BNP levels between the
MI and Sham mice is responsible for this difference. The study was
also done in NPR-A knock out mice to test whether this effect is
mediated by NPR-A as shown by our previous experiments.
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RESULTS
As shown in figure 20, our cryoinfarction model produced
myocardial cell death and fibrosis similar to what will be seen in
myocardial infarction. The infarction was limited to the area under the
application of the frozen probe and immediate surrounding myocardial
tissue without extension to the ventricular apex. AS a result no
ventricular aneurysms were observed in our model.
We tested and compared the degree of gastric emptying at one
and two week after infarction to establish the differences in plasma
BNP levels between the MI and sham mice. Subsequent experiments
on absorption were done at two weeks after infarction.
When gastric emptying was measured one week after infarction,
it was significantly decreased in the cryoinfarction group as compared
to the sham. Percent gastric emptying was 67.5% ± 5.8 for the MI
group vs. 88.7%

± 2.9 for the sham group (P<0.05, t-test) as shown

in figure 21. The plasma BNP levels were elevated in both groups but
significantly higher in the MI group as compared to the sham group.
BNP levels were 4292.2 ± 276.5 1 week after MI vs. 105.4 ±
11.3 in sham mice (n = 5, p<0.05, t test). BNP levels were 1964.7 ±
755 two weeks after MI, (n=5, p<0.05, t test compared to one week
post MI).
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Figure 20. Representative histological appearance of the
myocardium14 days after cryoinfarction.
Stain: Hematoxylin & Eosin
4x (Top); 20x of the boxed part (Bottom)

LV Cavity
LV Wall
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Figure 21. Comparison of percent gastric emptying in sham vs.

Percent Gastric Emptying

MI in Wild Type mice; one week after cryoinfarction
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WT mice, 67.5% ± 5.8% for mice with MI vs. 88.7± 2.9 % for
sham (n=7, P<0.05)

67

Figure 22. Comparison of percent gastric emptying in sham vs.

Percent Gastric Emptying

MI Wild Type mice, two weeks after cryoinfarction
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WT mice, 82.2% ± 0.5% for mice with MI vs. 97.9 ± 0.4 % for
sham (n=5, P<0.05) P= 0.017.

As shown in figure 22 above, two weeks after infarction, percent
gastric emptying values were also significantly lower in the MI group
as compared to the sham group 82.2% ± 0.5% for MI vs. 97.9 ± 0.4
% for sham (n=5, P<0.05).
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Figure 23. Comparison of Percent gastric emptying in sham vs.

Percent Gastric Emptying

MI NPR-A KO mice, two weeks after cryoinfarction
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KO mice, 84.6% ± 0.7% for mice with MI vs. 87.6 ± 054 % for
sham (n=6, P >0.05) P= 0.07
In NPR-A knock out mice, percent gastric emptying was identical
between the MI vs. the sham group 84.6% ± 0.7% for mice with MI
vs. 87.6 ± 054 % for sham (n=6, P >0.05).
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There was also a statically significant difference in the degree of
absorption measured in relative fluorescence units (RFU) in the plasma
following a gavage meal containing 22ml/kg of 22mg/ml 4 kDa FITC
dextran. In wild type mice, absorption was, 631.9 ± 121 (RFU)

for

the MI group vs. 349.8 ± 78.6 (RFU) for the sham group; n=6, P<
0.05.
Figure 24. Comparison of absorption measured in relative

Relative Fluorescence Units
(Plasma)

Plasma fluorescence units. Sham vs. MI, WT mice
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Absorption measured in Relative plasma fluorescence units
WT mice, 631.9 ± 121 for mice with MI vs. 349.8 ± 78.6 for sham
n=6, P< 0.05

(P=0.04)
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In NPR-A knockout mice the difference in absorption was not
statistically

significant.

Absorption

measured

in

Relative

plasma

fluorescence units in NPR-A KO mice was, 516.2 ± 107.3 for mice with
MI vs. 366.5 ± 39 for sham n=6, P> 0.05

(P=0.1).

Figure 25. Comparison of absorption measured in relative

Relative Fluorescence Units
(Plasma)

plasma fluorescence units. Sham vs. MI, NPR-A KO
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Absorption measured in Relative plasma fluorescence units
NPR-A KO mice, 516.2 ± 107.3 for mice with MI vs. 366.5 ± 39 for
sham n=6, P> 0.05

(P=0.1).
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DISCUSSION
The presence of dyspeptic symptoms in heart failure and during
acute myocardial ischemia has been known for a long time. Studies
done as early as 1966 have reported what was then described as
venostatic gastritis where venous congestion is believed to be the
cause of gastric pathology (Fixa et al., 1966). The presence of nausea,
vomiting and indigestion during acute myocardial infarction and in the
course of heart failure has also been extensively reported in the
literature (Abrahamsson & Thorén, 1973; Ahmed et al., 1978;
Camurça et al., 2004; Pasini et al., 1989; Wei 1988). Studies that
have looked into mechanisms of such an association have in the past
mainly pointed to a possible chemoreceptive or neurally mediated
reflex known as the Bezold-Jarish reflex (Chianca et al., 1997; Sleight,
1981).
Both ANP and BNP have previously been shown to have
cardioprotective

effect

during

acute

myocardial

infarction.

For

instance, the effect of ANP and BNP on renal salt handling was shown
to

be

specifically

enhanced

during

acute

myocardial

ischemia

irrespective of the level of activation of the renin angiotensin
aldosterone (RAS) system (Charles et al., 2003; Rademaker et al.,
2000). ANP was also shown to have important volume regulation role
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during acute heart failure induced by ventricular pacing (Lee et al.,
1989). Both BNP and ANP are also shown to have an inhibitory effect
on regional sympathetic activity in the kidney and the heart (BrunnerLa Rocca et al., 2001). While the pathways that lead to sympathetic
activity are not clearly understood, the end result of decreased
sympathetic activity is cardioprotective. Studies that looked at the
receptors involved in such processes have consistently shown that
these effects are mediated by cGMP coupled pathways. While some of
this effect is indirectly mediated via the renin angiotensin aldoseterone
(RAS) system, protective actions of guanylyl cyclase-A that are not
mediated by the RAS have also been shown (Li et al., 2002; Nakanishi
et al., 2005).
In our experiments, we tested the effect of acute myocardial
injury on gastric emptying at one and two weeks post infarction and
compared the results along with the plasma BNP levels. There was a
significant reduction in gastric emptying at one week in mice with
myocardial infarction compared to sham. It is interesting to note that
even the sham mice had a slightly lower rate of gastric emptying at
one week compared to controls (baseline values). As the BNP levels
were higher in sham mice than in controls, and the levels were
markedly higher in the infarcted mice than the sham mice, this is an
indication that BNP levels corresponded with the degree of gastric
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emptying. At two weeks post infarction, the sham mice had gastric
emptying statistically identical to controls where as infarcted mice
continue to show a markedly lower rate of gastric emptying, this again
indicates that the BNP levels significantly correspond with the degree
of gastric emptying adding evidence that BNP may be the major (or
one of the major) reasons for the observed differences. Since our data
shows that infarcted receptor knock out mice had no significant
difference in gastric emptying compared to sham, this validates our
assertion that the BNP difference played a role in the observed effect
and this effect is probably mediated through the NPR-A receptor.
Our absorption data for wild type mice is consistent with our
central hypothesis and infarcted mice did show significantly lower
absorption rate as compared to sham. The data in the knock out mice
in our experiment is less conclusive, since the knock out mice with MI
did show a reduced absorption compared to the sham mice. There are
several explanations for this finding. First of all, myocardial injury is
known to activate a series of systems other than the natriuretic
peptides, and secondly the process of absorption in the GI tract is also
likely to involve several different mechanisms. For instance the renin
angiotensin aldoseterone system is known to be activated with
myocardial injury, inflammatory mediators such as tissue growth
factor β and tumor necrosis factor are also a few of the cytokines that
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are released from infarcted myocardium and circulate in the plasma
with potential effects in the GI tract. Therefore the observed effects in
NPR-A knock out mice may be manifestations of activation of these
systems that would be expected to be intact in the NPR-A knock out
mice.
It has also been shown that intravenous volume expansion
decreased gastric emptying and permeability of the mucosa to water
and solutes and vagus nerve mediated neural mechanism were
postulated as mechanisms for such an effect (Chang EB and Rao MC.,
1994). It was also reported that acute blood volume expansion with
intravenous fluids decreased net sodium absorption in the jejunum of
rats and dogs (Duffy et al., 1978; Richet & Hornych, 1969). Moreover
experiments in human volunteers have shown that body position
changes such as recumbency and simulation of hemorrhage resulted in
significant increase in intestinal water and salt absorption (Sjövall et
al., 1986). Despite this known relationship between gut motility,
gastric

emptying

and

intestinal

absorption

on

one

hand

and

intravenous venous expansion and contraction on the other, most of
the studies that have investigated this relationship were limited to the
vagal

or

sympathetic

nervous

system.

Nevertheless,

with

the

knowledge base accumulated in the field of natriuretic peptides over
the past two decades, it is only logical to conjecture that at least some
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of the changes observed in gastric emptying and intestinal absorption
during acute MI or heart failure may be due to natriuretic peptides.
The data supporting the relationship between volume expansion
and gastric emptying and intestinal water and salt absorption is fairly
strong. What was missing was an experiment to directly and
specifically test whether the elevated natriuretic peptide levels (caused
by volume expansion or myocardial injury) corresponded with gastric
contractility, gastric emptying and absorption. Together with our
earlier findings that all the natriuretic peptides significantly decrease
gastric contractility, our data on BNP showing significant reduction of
gastric emptying and absorption; the confirmation of these findings in
an acute myocardial infarction model is a strong indication that plasma
BNP (and natriuretic peptide) elevation during acute MI and / or heart
failure is at least partly responsible for these observed effects. More
importantly, the previously confirmed effect of increased plasma
volume on gastric emptying and absorption is validated by our data to
be mediated by natriuretic peptides in general and by BNP in
particular. This finding strengthens the case for a humoral link
between the heart and the GI tract and opens up new avenues for
heart failure research. We believe further research in this area could
identify potential new targets for the treatment of heart failure.
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CHAPTER FIVE
BNP AND NON MUSCLE MYOSINS IN THE
GASTROINTETSINAL TRACT
INTRODUCTION
Myosins are proteins that are involved in mechanical force
generation and transduction. The characteristic myosin molecule is
composed of two heavy chain subunits measuring approximately 200
kDa each, which form a globular amino-terminal head region, and a
coiled carboxyl-terminal tail. The globular head region is noncovalently associated with two pairs of light chains of 20 and 17 kDa
(Kelley & Adelstein, 1990). Typically, myosins interact with another
protein; actin, in a process that involves the hydrolysis of ATP.
Classically such actomyosin interaction is discussed in the context of
muscle

contraction

and

relaxation.

However

expressed in non muscle tissue (Sellers, 2000).
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myosins

are

also

Figure 26. Schematic diagram of non muscle myosin-II

Adapted from Bresnick (1999)

In non muscle cells, the prototype non muscle myosin
type-II regulates actin organization into filaments and its
functions include maintaining the cell shape, cell division and cell
movement (Bresnick, 1999). Non muscle myosin-II is also
involved in epithelial cell attachment at the tight junction
regulating paracellular permeability (Hecht et al., 1996). Tight
junctions are integral part of the intestinal villi absorptive
structures.
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Intestinal Villi
Figure 27. Schematic depiction and electron micrograph of
the structures of intestinal villi

Adapted from Keith R. Porter and S Clark
The electron micrograph (above) shows the microvilli of a mouse
intestinal cell. Incorporated in the plasma membrane of the microvilli
are a number of enzymes, mucous producing goblet cells and
endocrine / paracrine cells that produce a number of hormones,
among which are the natriuretic peptides and guanylins.

79

Figure 28. Cytoskeletal structures of the intestinal microvillus.

Adapted from Ross, Histology: A Text and Atlas, 4th ed.
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Figure 29. Ultra structures of the microvilli cytoskeleton

A

B

Adapted from (Hirokawa & Heuser, 1981)
Actin cytoskeleton is shown by the arrow(s) in panel A, and in panel B
the quick freeze, deep etch, rotary replication images show the core of
the microvilli and its attachment at the cytoskeleton base in the
cytoplasm
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Figure 30. Transmission Electron micrograph of intestinal villi
in various state of contraction

Chicken

intestinal

epithelia

showing

increasing

state

of

contraction (top to bottom). Note ‘fanning’ of the microvilli as
the

degree

of

contraction

increase.

Transmission

electron

micrograph. Top; 6100x, middle; 5600 x and bottom 8900x.
Adapted from (Burgess, 1982)
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Tight Junctions
Tight junctions seal adjacent epithelial cells in a narrow band
just beneath their apical surface. They perform vital functions including
regulation of the passage of molecules and ions through the space
between cells and blocking of movement of the integral membrane
proteins between the apical and basolateral surfaces.

Figure 31. Schematic depiction of tight junctions

Studies done in kidney, bladder and intestinal epithelia
have

confirmed

changes

in

permeability

regulated

by

Phosphorylation related contractile changes at the tight junction.
These changes primarily increase paracellular movement of
water and small molecular weight solutes (Broschat et al., 1983;
Hecht et al., 1996; Keller & Mooseker, 1982; Swanljung-Collins
& Collins, 1992). Non muscle myosin type IIB is phosphorylated
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by casein kinase-II and dephosphorylated by a phosphatase that
is regulated through the action of Rho–associated kinase (Li &
Gorodeski, 2006).
Since the physiological effects of the natriuretic peptides
are mediated via cGMP dependant protein kinases, we found it
intriguing to examine whether treatment with BNP would reveal
changes

in

the

distribution

of

non

muscle

myosins

and

contractility pattern of the intestinal villi and thus shed some
light on the mechanism for the observed effect of BNP on
absorption.
We treated wild type mice with a 10 ng/g iv bolus of BNP
followed by a 1ng/minute infusion for 30 minutes. After the 30
minute infusion the mice were sacrificed and intestinal tissue
removed and sectioned into, jejunum, ileum and colon and
immunostained for non muscle myosin as described in the
methods section. We used the vehicle as an experimental
control. We also used a tissue section not treated with first
antibody as a methodological control to evaluate the potential
confounding by non specific binding.
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RESULTS
Figure 32. Toluidine blue stained 3µm sections of a mouse
intestinal tissues

Cross sections of intestinal tissue from our experiments are shown.
Top panel, Jejunum; middle panel, ileum; and bottom panel, colon.
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Figure 33. Higher magnification view of intestinal villi

Images shown are 3 µm section of Jejunal villi (top) and Ileum
(bottom), stained with toluidine blue. Magnification is 40x top, and
20x bottom.
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Figure 34. Electron micrograph of the intestinal microvilli
Control vs. BNP treated

Control, 20 000x

BNP treated, 20 000x

Microvilli in BNP treated mice show loss of the distinctive
‘fanning’ of the microvilli that is typical of markedly contracted
state.
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Figure 35. Jejunal villi immunostained for non muscle
myosin type IIB - Control

Longitudinal section at 20x (Top) and cross section 40x bottom
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Figure 36. Comparative images of control vs. BNP treated
jejunal villi

Images show jejunal villi, immunostained for non muscle myosin
type IIB. Control (TOP) and BNP treated (bottom). Note the
marked increase in fluorescence in BNP treated as compared to
control. Immunofluorescence, 20 x magnification.
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Figure 37. Jejunal villi and smooth muscle bundles
immunostained for non muscle myosin

Cross section view of the mouse ileum is shown. Note the
circular and longitudinal smooth muscle bundles with distinct
stain (fluorescence) for non muscle myosin type IIB. The core of
the villi also shows the distinct staining pattern.
Magnification, 10 x
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Figure 38. A 3 µm sections of a mouse jejunum immunostained
for non muscle myosin type IIB. Control vs. BNP

Control top and BNP treated bottom. Note the markedly increased
staining of the villus core and the crypt in BNP treated mouse. 20x
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DISCUSSION
Structures

necessary

for

force

generation

and

mechanotransduction such as actin and myosin and their
associated proteins are integral components of the cytoskeleton
of the intestinal villi (Mooseker, 1976; Mooseker et al., 1983;
Rodewald et al., 1976; Rostgaard & Thuneberg, 1972). Although
the mechanism of contraction of intestinal villi still remains
unsettled,

different

studies

have

reported

mechanisms

of

contraction that are both ATP and calcium dependent and others
reporting

calcium

independent

mechanisms

of

contraction

(Burgess, 1982; Mooseker, 1976; Swanljung-Collins & Collins,
1991). Still other studies have reported contraction at the tight
junctions but not of the microvilli themselves (Keller & Mooseker,
1982).
Our electron micrographic observations indicate that
elevation of BNP in the plasma appears to cause the microvilli to
loose the typical ‘fanning’ or separated appearance that is
characteristic of contraction at the crypt region of the intestinal
microvilli. Such appearance was previously shown to be due to
contraction

at

the

tight

junction

regions

circumferential contractile ring (Burgess, 1982).
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involving

a

Tight junction

contraction in turn results in increased paracellular permeability
(Hecht et al., 1996; Turner et al., 1997). Therefore our electron
micrographic observation (decreased contraction of the tight
junction contractile ring) supports the hypothesis that elevated
BNP in the plasma makes the tight junctions of intestinal villi less
permeable to water and small molecular weight solutes. Our
fluorescence

immunostaining

images

also

support

this

hypothesis as we show enhanced distribution of non muscle
myosins along the crypts of the villi; which may be an indication
that the enhanced distribution corresponds to a change in
tautness of the tight junctions thereby decreasing paracellular
movement while allowing apical transport of nutrients. Apical
transport of electrolytes and nutrients (sodium and glucose for
example) is mediated by the sodium glucose cotransporter
(SGLT1)

and

permeability
Physiologically

is
to

accompanied
small

such

by

solutes

coordination

increased

tight

junction

al.,

1997).

(Turner

et

between

the

apical

and

basolateral surfaces of the villus would be advantageous; as it
allows regulated (transporter mediated) absorption across the
apical membrane while directing water and small solutes to the
tight junction. However whenever there is a need to decreases
volume, as in the case of heart failure; decreasing free
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paracellular movement of water while still permitting apical
transport of nutrients would allow for a more homeostatic
absorptive

function;

especially

when

modulating

volume

becomes essential as in the case of heart failure. Utilizing BNP
and possibly the other natriuretic peptides for this process would
have physiological benefit for the heart; after all the heart will be
‘interested’ in getting all the nutrients it can get during heart
failure while delaying or decreasing absorption of water and salt
that could add to its stress.
Although the effect of BNP and natriuretic peptides in
general on permeability of intestinal epithelia has not been
extensively studied in the past, it is known that natriuretic
peptides in general have an effect on permeability of the
vascular epithelium (He et al., 1998; Huxley et al., 1987; Kubes,
1993; Lofton et al., 1990). Studies that have looked into this
effect of ANP and BNP on permeability of

pulmonary vascular

epithelium have shown that these effects were at least partially
reproduced by cGMP or cGMP analogs (Draijer et al., 1995;
Hölschermann et al., 1997; Klinger et al., 2006; Westendorp et
al., 1994). A more direct effect that is independent of cGMP was
also shown for ANP (Kubes, 1993). Similarly, other studies that
have investigated the effect of ANP on counteracting the
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endothelial permeability and inflammatory effect of

tumor

necrosis factor (TNF) have shown that this effect is mediated by
NPR-A and cGMP and it is targeted at cytoskeletal actin
organization (Kiemer et al., 2002).

An other support for this

finding comes from the observation that vascular endothelial
growth factor (VEGF) is inhibited by ANP (Pedram et al., 2002).
VEGF is also known as vascular permeability factor and is
involved in stabilization of actin association with tight junctions;
and this function was reversed by guanylyl cyclase receptor
antagonists (Pedram et al., 2002). The precise mechanism of
this process is still unclear, some studies indicated it involves
heat shock protein 27 (HSP27); a protein with known functions
in actin organization and whose actions are mediated by cGMP
dependent protein kinase (Butt et al., 2001). Other studies
suggest mechanisms that involve Phosphorylation of structural
and contractile proteins; including actin and

myosin (Hecht et

al., 1996; Ma et al., 2000; Turner et al., 1997), Specifically at
the prejunctional ring of actin and myosin; sites that are
characteristic of contractile function at the tight junction (Madara
et al., 1987).
Our immunofluorescene images revealed an enhanced
distribution of non muscle myosins in the intestinal villi core and
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along the crypts (tight junctions). While we haven’t done
biochemical analysis to correspond with these findings, previous
studies have shown that Phosphorylation related proteins such
as mitogen-activated protein (MAP) kinase and Rho of the ras
family of proteins are associated with tight junctions and this in
turn controls tight junction contractility (Murakami et al., 1994;
Zahraoui et al., 1994). Interestingly, both ANP and BNP are
known to exert anti inflammatory (thus decreased vascular
endothelium

permeability)

effects

in

vascular

endothelium

through mechanisms that involve MAP-kinase and MAP kinase
phosphatase-1 (MKP-1) (Fürst et al., 2005; Weber et al., 2003).
Although more research needs to be done in this direction,
our electron micrographic imaging and immunostaining data
coupled with what is previously known about epithelial tight
junction function lends enough support to our hypothesis and
helps formulate a basis for future direction. The finding that
immunostaining of non muscle myosin in BNP treated mouse
tissue shows enhanced distribution of non muscle myosins along
the crypts and core of the intestinal microvillus appears to be a
recurring theme. Tight junctions appear to contract less and
microvilli assume the typical non-contracting appearance when
BNP plasma level was raised. These findings are associated with
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decreased paracellular permeability at least in the case of the
vascular

endothelium.

Whether

the

biochemical

signaling

mechanisms known for vascular endothelium will be the same in
the intestinal villi and whether it will have similar physiological
consequences remains to be investigated.
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CHAPTER SIX
SUMMARY AND CONCLUSIONS
The main objective of my study was to show that there indeed is
a humoral link between the heart and the gastrointestinal system. This
humoral link appears to utilize natriuretic peptides although it is
possible that there probably are several other as yet undiscovered
peptides or even other molecules that serve this same purpose.
To this aim, we demonstrated that ANP, BNP and CNP decreased
contractility of gastric smooth muscle in the whole intact animal.
Confirming the previously done in vitro experiments that showed
natriuretic peptides decreased contractility of isolated gastric and
intestinal smooth muscle cells. This effect was shown to have a
functional significance in that; these experiments showed that gastric
emptying and absorption from the gut were decreased in the whole
animal when BNP was intravenously administered. We also presented
data showing myocardial injury and the associated elevation in plasma
BNP levels decreased gastric emptying and absorption from the GI
tract. Although the obvious reason for this result may be the effect of
BNP on smooth muscle relaxation, we also show data supporting the
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hypothesis that BNP and natriuretic peptides have a more direct effect
on absorptive structures of the intestinal villi possibly affecting
paracellular transport of water and electrolytes.
In summary one can garner the following observations from
these experiments
a) Natriuretic peptides decrease gastric contractility and gastric
emptying in intact whole animals
b) BNP decreased gastric empting in a dose dependant manner
c) BNP decreased absorption from the GI tract when administered
at dose designed to raise the plasma level to the levels seen in
heart failure
d) Myocardial injury and elevation of BNP in the plasma was
associated with decreased gastric emptying and absorption
e) Elevated plasma BNP has en effect on contractile structures of
the intestinal villi and this effect appears to be directed at
decreasing paracellular movement of water and solutes
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PERSPECTIVES
The next line of research should follow the intriguing questions
raised by our immunofluorescnece data. How and why does the
distribution of myosin in the microvilli appear to be increased by BNP?
What are the molecular mechanisms that are involved here? Is the
electron micrograph appearance of microvilli indication of contraction
at the tight junction? Is paracellular movement of water and solutes
decreased by BNP as suggested by our imaging data? Are there other
transporters that direct water and sodium absorption to the basal and
apical membranes; if so can they be therapeutically targeted to
regulate sodium absorption from the gut? Would that be beneficial in
heart failure treatment?
Heart failure remains to be a major public health problem. Its
annual cost to the health care field is growing every year and currently
stands at over 30 Billon US dollars. Despite remarkable advances in
the treatment of coronary disease and the risk factors associated with
it, the incidence and prevalence of heart failure has only increased. In
spite of all this, there hasn’t been a major breakthrough in heart
failure treatment for many decades. Of course targeting the gut to
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treat the heart seems a bit far fetched at this point in time. However,
the GI tract is a complex organ, perhaps even tantamount to having
many organs in one. The experimental results presented here
strengthen the case for a direct humoral link and interplay between
the heart and the GI tract. Further understanding of this link and
characterization of the signaling process involved is likely to be a
major advance in heart failure treatment.
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APPENDIX A
Abbreviations Used
ACE – Angiotensin converting enzyme
ANF - Atrial natriuretic factor
ANOVA - Analysis of variance
ANP – Atrial natriuretic peptide
AT1 – Angiotensin II receptor type 1A
BNP – B-type natriuretic peptide
cANF – c-Atrial natriuretic factor (peptide)
cGMP – Cyclic guanylyl mono phosphate
CNP – C-type natriuretic peptide
DMSO – Dimethyl sulfoxide
DNP – Deandropsis natriuretic peptide
FITC – Fluorescein-isothiocyanate
GC – guanylyl cyclase
GI – Gastrointestinal
GTP – Guanylyl tri phosphate
i.d. – Internal diameter
i.v. – Intravenous
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i.P. – Intraperiotneal
KDa – Kilo Dalton
KHD – Kinase homology domain
KO – Knockout
LAD – Left anterior descending artery
LSD – Least square difference
LV – Left ventricle
MAP – Mitogen activated pathway
MI – Myocardial infarction
MKP – Mitogen activated kinase phosphatase
NPR-A – Natriuretic peptide receptor type –A
NPR-B - Natriuretic peptide receptor type –B
NPR-C - Natriuretic peptide receptor type –C
o.d. – Outside diameter
PBS – Phosphate buffered saline
PDE – Phosphodiesterase
PIC- Probe induction catheter
PKG – Protein kinase G
RFU – Relative fluorescence units
RIA – Radioimmunoassay
RV – Right ventricle
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TNF – Tumor necrosis factor
VEGF – Vascular endothelium derived growth factor
WT – Wild type
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